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ABSTRACT
Discontinuation of maintenance therapy against toxoplasma encephalitis (TE) for individuals infected
with human immunodeﬁciency virus (HIV) who are receiving successful anti-retroviral therapy is
considered safe. Nevertheless, there are few published studies concerning this issue. Within the setting
of the Swiss HIV Cohort Study, this report describes a prospective study of discontinuation of
maintenance therapy against TE in patients with a sustained increase of CD4 counts to > 200 cells ⁄ lL
and 14% of total lymphocytes, and no active lesions on cerebral magnetic resonance imaging (MRI). In
addition to clinical evaluation, cerebral MRI was performed at baseline, and 1 and 6 months following
discontinuation. Twenty-six AIDS patients with a history of TE agreed to participate, but three patients
(11%) could not be enrolled because they still showed enhancing cerebral lesions without a clinical
correlate. One patient refused MRI after 6 months while clinically asymptomatic. Among the remaining
22 patients who discontinued maintenance therapy, one relapsed after 3 months. During a total follow-
up of 58 patient-years, there was no TE relapse among the patients who had remained clinically and
radiologically free of relapse during the study. Thus, discontinuation of maintenance therapy against TE
was generally safe, but may fail in a minority of patients. Patients who remain clinically and
radiologically free of relapse at 6 months after discontinuation are unlikely to experience a relapse of TE.
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INTRODUCTION
Toxoplasma encephalitis (TE) is a frequent com-
plication in patients with advanced human
immunodeﬁciency virus (HIV) infection who are
seropositive for Toxoplasma gondii [1,2]. Treatment
with pyrimethamine in combination with either
sulphadiazine or clindamycin is highly effective,
but is tolerated poorly [3]. After initial high-dose
treatment for c. 6 weeks, lifelong maintenance
therapy with lower doses of the same regimen
was normal before the era of potent anti-retroviral
combination therapy (ART) [4]. Before the intro-
duction of ART, relapse of TE occurred clinically
in up to 80% of patients within 6 months of
discontinuation of maintenance therapy [5]. Con-
sequently, it is important to accumulate data
concerning the safety of discontinuing mainten-
ance therapy in patients with immune restoration
while on ART.
It has been shown that it is safe to discontinue
primary prophylaxis against TE and Pneumocystis
pneumonia in patients on ART with a sustained
increase in CD4 cell count to > 200 ⁄ lL and 14% of
total lymphocyte counts [6,7]. The US Public
Health Service and the Infectious Disease Society
of America recommend that consideration should
be given to discontinuing maintenance therapy for
TE among asymptomatic patients with a sustained
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increase in CD4 T-lymphocyte count to > 200
cells ⁄ lL [8,9]. Several previous studies have repor-
ted that it is safe to interrupt maintenance therapy
for TE [10–12]. Kirk et al. [13] analysed seven
European HIV cohorts and found a relapse rate
for TE of 0.88 ⁄ 100 patient-years of follow-up. In a
preliminary report of a prospective randomised
trial, no episodes of TE relapse occurred in either
group during a follow-up period of 12 months (7th
Conference on Retroviruses and Opportunistic
Infections, San Francisco, 2000; abstract 230).
The aim of the present study was to investigate
the incidence of TE relapse in a well-deﬁned
population with a sustained increase in CD4 cell
count while receiving ART, and in the absence of
focal signs on magnetic resonance imaging (MRI).
PATIENTS AND METHODS
The Swiss HIV Cohort Study
This was a prospective multicentre study within the frame-
work of the Swiss HIV Cohort Study (SHCS), which is a
prospective cohort study with continuing enrolment of adult
patients infected with HIV-1 [14]. All patients provide written
informed consent. Follow-up of patients occurs at one of seven
outpatient clinics. Enrolment for the SHCS is independent of
the stage of disease or the degree of immunosuppression, and
information is collected according to standardised criteria.
Clinical status is deﬁned according to the 1993 classiﬁcation
system for HIV infection established by the CDC. CD4 cell
counts are measured using ﬂow cytometry. Plasma HIV RNA
levels are measured using the Amplicor assay (Roche, Basel,
Switzerland), which has a lower limit of detection of 200
copies ⁄mL. An ultrasensitive modiﬁcation of the assay, with a
detection limit of 2–40 copies ⁄mL, was introduced in 1998 [15].
Deﬁnition of toxoplasma encephalitis
Within the SHCS (http://www.shcs.ch), the diagnosis of TE
can be deﬁnitive or presumptive. A deﬁnitive diagnosis of TE
is made on the basis of positive histological or cytological
ﬁndings of brain lesions. The date of diagnosis is the date of
brain biopsy. A presumptive diagnosis of TE is made if there is
a recent onset of focal neurological abnormality consistent with
intra-cranial disease, or reduced level of consciousness, or
headache, with computer tomography or MRI scan evidence of
at least one lesion having a mass effect or enhancing with
contrast medium, and if there is a response to speciﬁc
treatment against T. gondii, as shown in a repeat scan and ⁄ or
by clinical improvement. The date of diagnosis is the date of
the scan.
Study design
The enrolment period for the present study began in May 2000.
Subjects receiving maintenance therapy against TE were
eligible: (i) if they had an ART-induced increase in CD4 cell
count to ‡ 200 ⁄ lL and 14% of the total lymphocyte count,
sustained for > 12 weeks, as determined on two occasions at
least 12 weeks apart, and a plasma viral load of < 30 000
copies ⁄mL at enrolment; and (ii) if they had been receiving TE
maintenance therapy for at least 6 months. Patients fulﬁlling
these criteria underwent gadolinium-enhanced cerebral MRI. If
there was no sign of focal inﬂammation, the patients were
eligible for the study of discontinuation of maintenance
therapy. Exclusion criteria were recurrent oropharyngeal
thrush and pharmacological immunosuppression; however,
corticosteroids of < 10 mg prednisone equivalent ⁄day, and ⁄ or
hydroxyurea at a dosage of £ 500 mg twice-daily were allowed.
At study entry, maintenance therapy against TE was
discontinued. To detect relapse of TE, clinical assessment of
neurological symptoms was performed at months 1, 3 and 6.
Cerebral MRI examination with gadolinium enhancement was
performed at months 1 and 6. CD4 cell counts and virus loads
were measured at enrolment, and at months 3 and 6. The
endpoint of the study was relapse of TE, as shown by new
inﬂammatory activity of old TE lesions, or new lesions in MRI
and ⁄ or neurological deterioration. In this 6-month follow-up
study with intensive clinical and radiological monitoring, the
earliest start date was May 2000, and the last follow-up date
was September 2003.
MRI scans were performed in the institution where the
patients attended for follow-up. The local radiologist inter-
preted the scans; only if there were ﬁndings suggestive of new
inﬂammatory activity were the images sent to the coordinating
centre. If the principal investigator agreed with the ﬁnding, it
was counted as an event. Eighteen months after the end of the
study, the long-term outcome for the patients who remained
relapse-free during the 6-month study period was assessed
using the SHCS database of February 2005. The incidence of
late relapse was calculated assuming a Poisson distribution of
events and the upper 95% CI of incidence was calculated.
RESULTS
Patient characteristics
The ﬂow chart of the study is summarised in
Fig. 1. Twenty-six patients fulﬁlling the CD4
count entry criteria were evaluated by cerebral
26 patients
Fulfilled non-radiological inclusion criteria
3 (12%)
Disease activity in MRI at baseline 
23
1 refused MRI at month 622
1 (5%)
Relapse of toxoplasma encephalitis 
21
Successful
discontinuations of 
maintenance therapy
Fig. 1. Flow-chart of the study of discontinuation of
maintenance therapy against toxoplasma encephalitis.
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MRI. Three (11%; 95% CI 2–30%) showed peri-
focal gadolinium enhancement at baseline and
were excluded from discontinuation of mainten-
ance therapy. The characteristics of these patients
are shown in Table 1.
In total, 23 patients without active MRI lesions
discontinued maintenance therapy. All but one
had a previous presumptive diagnosis of TE.
Nine patients were treated for TE with sulphadi-
azine and pyrimethamine, six with pyrimetha-
mine and clindamycin, and eight with other
combinations at the time of discontinuation. No
patient was lost to follow-up, but one patient who
refused MRI follow-up after 6 months was exclu-
ded from analysis. In this patient there were no
clinical signs of a relapse of TE after 6 months.
The baseline characteristics of the 22 patients
who discontinued maintenance therapy and had
complete radiological follow-up are shown in
Table 1. All the patients continued ART during
the study, except one who participated in a trial of
structured treatment interruption [16]. At study
entry, the median CD4 cell count was 434 cells ⁄ lL
(range 218–875) and 22% (range 15–40) of total
lymphocytes; 17 patients had plasma HIV RNA
levels of < 50 copies ⁄mL, and two had levels of
> 1000 copies ⁄mL. MRI was performed at
1 month after withdrawal of maintenance ther-
apy, and again after 6 months. During follow-up,
the CD4 counts in all but one patient were
maintained at levels equal to or higher than that
at baseline. At month 6, one patient had an
absolute CD4 count of 163 cells ⁄ lL, correspond-
ing to 29% of peripheral lymphocytes, during a
phase of transient peripheral lymphocytopenia
that resolved within 3 months. This patient did
not restart maintenance treatment. Five of the
enrolled patients were also analysed in the multi-
cohort survey by Kirk et al. [13].
Relapse of TE
One relapse of TE occurred in a patient at
3 months following discontinuation of mainten-
ance therapy. This was a male patient, aged
40 years, with a history of injecting drug use, who
presented with new neurological symptoms.
Signs of a cerebellar and left pyramidal syndrome
could be explained by gadolinium-enhancing
lesions in the MRI compatible with an inﬂamma-
tory reactivation of TE. Before entering the study,
this patient had been treated with sulphadiazine
and pyrimethamine for 50 months. The patient’s
lowest CD4 cell count was 8 ⁄ lL; the CD4 cell
count at the time of discontinuation of mainten-
ance therapy was 307 ⁄ lL (16%); and the CD4 cell
count at the time of relapse was 354 ⁄ lL (14%).
Plasma HIV RNA was < 20 copies ⁄mL at study
entry and at the time of relapse. The patient
commenced treatment with sulphadiazine and
pyrimethamine and recovered. This patient was
not analysed in the study by Kirk et al. [13].
No patient experienced a clinical neurological
deterioration in the absence of new MRI abnor-
malities, and no new MRI abnormalities were
detected in the remaining patients.
Based on one relapse among 22 patients who
had a complete documented follow-up, the pro-
portion of relapsing patients was 4.5% (95% CI
0.1–23%).
Table 1. Characteristics of the
patients with toxoplasma encephal-
itis who fulﬁlled the CD4 count
study data criteria
Characteristics
Patients discontinuing
maintenance therapy
Patients with inﬂammatory
lesions at baseline MRIa
Total number of patients 22 3
Female 8 (36%) 1 (33%)
Age in years, median (range) 39 (30–61) 41, 48, 63
HIV-transmission mode
Men who have sex with men 7 (32%) 1 (33%)
Injecting drug user 6 (27%)
Heterosexual 9 (41%) 2 (67%)
Duration of TE treatment in months, median (range) 48 (19–81) 16, 26, 32
Duration of ART in months, median (range) 43 (9–76) 14, 24, 32
CD4 count (cells ⁄ lL) at TE diagnosis, median (range) 40 (4–230) 150, 40, 126
CD4 count (cells ⁄ lL) at discontinuation, median (range) 418 (260–630) 218, 875, 600
CD4 percentage at discontinuation, median (range) 22% (15%-32%) 30%, 40%, 18%
Plasma HIV RNA (copies ⁄mL) at discontinuation,
median (range)
< 50 (< 50–5920) < 50, 158, < 50
Participants with plasma HIV RNA <50 copies ⁄mL 17 (77%) 2 (66%)
aFor the three patients with inﬂammatory lesions, individual values are given instead of median (range) where
shown.
ART, anti-retroviral therapy; HIV, human immunodeﬁciency virus; MRI, magnetic resonance imaging; TE,
toxoplasma encephalitis.
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Long-term follow-up
At the SHCS database download of February
2005, all the patients who had successfully dis-
continued maintenance therapy during the study
remained free of TE relapse without having
restarted drugs with anti-toxoplasmic activity.
The median CD4 cell count at the last follow-up
visit was 585 cells ⁄lL (range 283–1101), and 18
(86%) had plasma HIV RNA of < 50 copies ⁄mL.
Median follow-up was 43 months (range 18–
50 months) after discontinuation. The total fol-
low-up time for patients remaining free of relapse
after the 6-month study period was 58 person-
years. The upper 95% CI for incidence of relapse
was therefore 5 ⁄ 100 patient-years for patients
who remained clinically and radiologically re-
lapse-free at 6 months following discontinuation
of maintenance therapy.
In order to compare the results with studies
published previously, the long-term incidence
was calculated for all 23 patients who fulﬁlled
the entry criteria and discontinued maintenance
therapy, assuming a Poisson distribution of
events. Thus, the patient who refused MRI ima-
ging after 6 months was also included in this
analysis. The median follow-up after discontinu-
ation was 44 months, and the total follow-up time
was 76.4 patient-years. The long-term incidence
rate was thus 1.3 relapses ⁄ 100 patient-years (95%
CI 0.03–7.2) (Table 2).
Outside the study protocol, the three patients
with MRI activity at baseline were re-evaluated
by MRI scan after 12, 24 and 35 months, respect-
ively. These patients no longer showed any MRI
activity, and maintenance therapy was discontin-
ued at CD4 cell counts of 609, 817 and 575
cells ⁄ lL, respectively. During follow-up periods
of 18, 8 and 15 months, respectively, no TE
relapses were detected.
DISCUSSION
The aim of this prospective study was to investi-
gate whether maintenance therapy against TE can
be discontinued safely in patients with a sus-
tained immunological response to ART. To our
knowledge, this is the second published study to
suggest that discontinuation of maintenance ther-
apy against TE may not be safe in a minority of
patients, despite sustained immunological and
virological response to ART. Kirk et al. [13]
reported one of 75 patients who relapsed at
1 month after discontinuing maintenance ther-
apy, despite the fact that the patient had sup-
pressed plasma HIV RNA and a CD4 cell count of
> 300 cells ⁄ lL. Gadolinium-enhanced MRI is a
powerful tool for studying the inﬂammatory
activity of brain lesions [17–19]. It is very likely
that changes would be detectable by MRI within a
few weeks following TE relapse, although there
are no hard data concerning this issue.
Inﬂammatory TE activity can be detected by
MRI without clinical signs, as exempliﬁed by the
patients who could not be enrolled in the present
study because of radiologically active contrast-
enhancing lesions. It is not known whether such
lesions would progress to a clinical relapse of TE
if anti-protozoal drugs were stopped. Neverthe-
less, it was considered that these three partici-
pants might have a substantial risk of a relapse of
TE, and they were counselled to continue main-
tenance therapy. Neither these three patients, nor
the patient who suffered a relapse after discon-
tinuing therapy, differed signiﬁcantly with regard
to the period of ART treatment, the CD4 cell count
at the time of discontinuation of maintenance
therapy, or the virological response to ART.
Therefore, it is not possible to predict the safety
of discontinuation based on an individual
patient’s history or routine laboratory markers.
Table 2. Comparison of incidence rates in published studies of discontinuation of maintenance therapy against
toxoplasma encephalitis (TE)
Study (location,
year of publication)
Study
type Inclusion criteria
No of
patients
Median
follow-up,
months
Patient-
years of
follow-up
Number
of TE
relapses
Incidence per 100
Patient-years
(95% CI)
Soriano et al. (Spain, 2000) [11] RCS CD4 cells > 100 ⁄ lL and plasma
HIV RNA <5000 ⁄mL after
3 months of ART
9 18 16.5 0 0 (0–18)
Zeller et al. (France, 2001) [12] RCS CD4 cells > 200 ⁄ lL and on ART 19 20 NA 0 0 (NA)
Kirk et al. (Europe, 2001) [13] RCS CD4 cells > 200 ⁄ lL and on ART 60 18 92 1 1.1 (0–6.1)
Current study (Switzerland, 2005) PS CD4 cells > 200 ⁄ lL and 14% for
at least 12 weeks and on ART
23 43 76 1 1.3 (0–7.2)
PS, prospective study; RCS, retrospective analysis within cohort studies; NA, not available.
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It can be hypothesised that deﬁcits in the
speciﬁc immune response to T. gondii that were
not reversible during ART could be responsible
for relapse. Indeed, reconstitution of speciﬁc
immune responses during ART against different
opportunistic infections has been demonstrated,
and is associated with successful discontinuation
of secondary prophylaxis [20–23]. However, the
assays to quantify cellular immune responses are
not standardised, their predictive value for reac-
tivation of the infection has not been established,
and therefore their use in the routine clinical
setting cannot be recommended.
The present study has several limitations. The
small sample size does not allow a precise
estimate of the risk for reoccurrence of TE, as
shown by the large 95% CI for the failure rate. In
addition, radiological follow-up at 6 months does
not rule out a higher radiological failure rate
during long-term follow-up. However, the fact
that there was no clinical diagnosis of TE at 2–
4 years after discontinuation of maintenance ther-
apy in the enrolled patients argues against any
substantial risk of late relapses if relapse does not
occur during the ﬁrst 6 months following discon-
tinuation and immune-reconstitution is main-
tained. This conclusion is supported by the
report of Kirk et al. [13], in which the only
observed relapse occurred at 1 month after dis-
continuation of maintenance therapy.
In conclusion, TE relapse may occur after
discontinuation of maintenance therapy, even in
those patients with a sustained rise in CD4
lymphocytes to > 200 cells ⁄ lL who are receiving
virologically successful ART. Neuroimaging be-
fore discontinuation, and close clinical (and prob-
ably radiological) monitoring, is warranted in this
situation. After weighing the risk of reoccurrence
against the negative effects of continuation of
maintenance therapy, discontinuation may be
indicated for most patients. Larger series of
patients are needed to delineate whether the
beneﬁts of discontinuation of antimicrobial drugs
outweigh the risk of relapse, and whether
neuroimaging is mandatory in this setting.
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